Lipocine Company Profile (NASDAQ:LPCN)

About Lipocine (NASDAQ:LPCN)

Lipocine logoLipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LPCN
  • CUSIP: N/A
  • Web:
  • Market Cap: $78.6 million
  • Outstanding Shares: 21,186,000
Average Prices:
  • 50 Day Moving Avg: $3.98
  • 200 Day Moving Avg: $4.04
  • 52 Week Range: $3.03 - $5.33
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.15
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.22 per share
  • Price / Book: 3.04
  • EBITDA: ($16,590,000.00)
  • Return on Equity: -64.49%
  • Return on Assets: -59.80%
  • Current Ratio: 9.66%
  • Quick Ratio: 9.66%
  • Average Volume: 213,645 shs.
  • Beta: 2.02
  • Short Ratio: 6.01

Frequently Asked Questions for Lipocine (NASDAQ:LPCN)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

How were Lipocine's earnings last quarter?

Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.01. View Lipocine's Earnings History.

When will Lipocine make its next earnings announcement?

Lipocine is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Lipocine.

Where is Lipocine's stock going? Where will Lipocine's stock price be in 2017?

3 equities research analysts have issued 1 year price objectives for Lipocine's shares. Their predictions range from $11.00 to $38.00. On average, they expect Lipocine's stock price to reach $24.67 in the next year. View Analyst Ratings for Lipocine.

Who are some of Lipocine's key competitors?

Who are Lipocine's key executives?

Lipocine's management team includes the folowing people:

  • Mahesh V. Patel Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Morgan R. Brown CPA, Chief Financial Officer, Executive Vice President
  • Gregory Bass, Executive Vice President, Chief Commercial Officer
  • Stephen Anthony Hill M.D., Lead Independent Director
  • Jeffrey A. Fink, Director
  • Richard Dana Ono, Director
  • John W. Higuchi, Non-Executive Director

How do I buy Lipocine stock?

Shares of Lipocine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Lipocine's stock price today?

One share of Lipocine stock can currently be purchased for approximately $3.71.

MarketBeat Community Rating for Lipocine (NASDAQ LPCN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  115 (Vote Outperform)
Underperform Votes:  49 (Vote Underperform)
Total Votes:  164
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Lipocine (NASDAQ:LPCN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $24.67 (564.87% upside)
Consensus Price Target History for Lipocine (NASDAQ:LPCN)
Price Target History for Lipocine (NASDAQ:LPCN)
Analysts' Ratings History for Lipocine (NASDAQ:LPCN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017Roth CapitalSet Price TargetBuy$38.00MediumView Rating Details
8/7/2017Canaccord GenuitySet Price TargetBuy$11.00LowView Rating Details
4/26/2017HC WainwrightReiterated RatingBuy$25.00LowView Rating Details
(Data available from 10/23/2015 forward)


Earnings History for Lipocine (NASDAQ:LPCN)
Earnings by Quarter for Lipocine (NASDAQ:LPCN)
Earnings History by Quarter for Lipocine (NASDAQ LPCN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.30)($0.31)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.30)($0.26)ViewN/AView Earnings Details
3/6/2017Q4 2016($0.28)($0.16)ViewN/AView Earnings Details
8/9/2016Q2($0.37)($0.32)ViewN/AView Earnings Details
5/9/2016Q1($0.33)($0.38)ViewN/AView Earnings Details
3/10/2016Q4 2015($0.29)($0.25)ViewN/AView Earnings Details
11/12/2015Q3($0.35)($0.35)ViewN/AView Earnings Details
8/11/2015Q2 2015($0.20)($0.26)ViewN/AView Earnings Details
5/7/2015Q1 2015($0.35)($0.23)ViewN/AView Earnings Details
3/11/2015Q4 2014($0.35)($0.32)ViewN/AView Earnings Details
11/10/2014Q3 2014($0.58)($0.32)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.42)($0.55)ViewN/AView Earnings Details
5/13/2014Q1 2014($0.35)($0.41)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Lipocine (NASDAQ:LPCN)
2017 EPS Consensus Estimate: ($0.95)
2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.20)($0.20)($0.20)
Q2 20172($0.33)($0.31)($0.32)
Q3 20172($0.28)($0.12)($0.20)
Q4 20172($0.30)($0.15)($0.23)
Q1 20181$0.82$0.82$0.82
Q2 20181($0.32)($0.32)($0.32)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Lipocine (NASDAQ:LPCN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Lipocine (NASDAQ:LPCN)
Insider Ownership Percentage: 11.30%
Institutional Ownership Percentage: 26.39%
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Institutional Ownership by Quarter for Lipocine (NASDAQ:LPCN)
Insider Trades by Quarter for Lipocine (NASDAQ:LPCN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/30/2015John W HiguchiDirectorBuy5,000$12.68$63,400.00View SEC Filing  
9/30/2015Mahesh V. PatelCEOBuy4,000$11.84$47,360.00View SEC Filing  
11/25/2014Mahesh V PatelCEOBuy2,000$5.10$10,200.00View SEC Filing  
11/24/2014Mahesh V PatelCEOBuy2,000$5.45$10,900.00View SEC Filing  
11/19/2014Richard Dana OnoDirectorBuy4,000$5.14$20,560.00View SEC Filing  
11/14/2014Mahesh V PatelCEOBuy2,000$5.06$10,120.00View SEC Filing  
11/13/2014Mahesh V PatelCEOBuy2,000$5.05$10,100.00View SEC Filing  
11/13/2014Stephen A HillDirectorBuy4,000$4.95$19,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Lipocine (NASDAQ:LPCN)
Latest Headlines for Lipocine (NASDAQ:LPCN)
Loading headlines, please wait.



Lipocine (LPCN) Chart for Monday, October, 23, 2017

This page was last updated on 10/23/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.